Literature DB >> 2898970

Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm.

D Verotta1, L B Sheiner.   

Abstract

An algorithm and computer program is presented that fits a largely non-parametric model to pharmacokinetic (PK) and pharmacodynamic (PD) data; it is an extension of a recently proposed approach. A PK model relates dose to plasma concentrations (Cp), a link model relates plasma concentrations to the concentration in the effect site (Ce), a PD model relates Ce to the effect. Both the PK and the PD model are non-parametric, but the link model is parametric. The extension presented here allows modeling of PK/PD data arising from non-steady-state experiments after arbitrary dosage. In addition, several data sets from the same individual (or from different individuals) can now be analyzed simultaneously, assuming the same link model for all, but allowing either all the PD models to be the same, or all to be different.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2898970     DOI: 10.1093/bioinformatics/3.4.345

Source DB:  PubMed          Journal:  Comput Appl Biosci        ISSN: 0266-7061


  16 in total

1.  Pharmacokinetics and effects of levodopa in advanced Parkinson's disease.

Authors:  E Bredberg; J Tedroff; S M Aquilonius; L Paalzow
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Pharmacodynamic modelling. Application to new drug development.

Authors:  P D Kroboth; V D Schmith; R B Smith
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 3.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

4.  Estimating the rate of thiopental blood-brain equilibration using pseudo steady state serum concentrations.

Authors:  P O Maitre; M Bührer; S L Shafer; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1990-06

5.  The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.

Authors:  B Tuk; M Danhof; J W Mandema
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

6.  Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure.

Authors:  A Bortolotti; D Castelli; D Verotta; M Bonati
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Apr-Jun       Impact factor: 2.441

7.  Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol.

Authors:  E H Cox; C A Knibbe; V S Koster; M W Langemeijer; E E Tukker; R Lange; P F Kuks; H J Langemeijer; L Lie-A-Huen; M Danhof
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

8.  Relationship between etomidate plasma concentration and EEG effect in the rat.

Authors:  P De Paepe; G Van Hoey; F M Belpaire; M T Rosseel; P A Boon; W A Buylaert
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

9.  Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis.

Authors:  M A Tabrizi-Fard; H L Fung
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

10.  Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605).

Authors:  R P Brueckner; L Fleckenstein
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.